Recognition and Treatment of ADHD in Adolescents and Adults

A CME/CE-Certified On-Demand Symposium

August 2009 to August 31, 2010

Estimated Time to Complete

Module 1: 15 minutes

Module 2: 30 minutes

Module 3: 15 minutes

Sponsored by Veritas Institute for Medical Education, Inc.

Supported by an educational grant from McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC.

Program Overview

Attention-deficit/hyperactivity disorder (ADHD) is associated with significant impact for the individual patient as well as for society. Older adolescent and adult patients experience a spectrum of disorder-related functional impairments that are associated with considerable educational and occupational underachievement. In the United States, the loss of workforce productivity associated with ADHD has been estimated at $67 billion to $116 billion.

Overall, ADHD remains undertreated and underrecognized. According to the National Comorbidity Survey Replication, of the 4.4% of adults who have ADHD, only 11% were treated within the past year. These data reinforce the ongoing need to educate clinicians concerning the recognition and treatment of ADHD.

Click on the name of a faculty member to view full bio, and click once more to close bio.

Co-chairs

Professor, Clinical Psychiatry

UCLA Semel Institute for Neuroscience and Human Behavior

Los Angeles, California

Associate Professor, Psychiatry

Harvard Medical School

Director, Substance Abuse Services

Clinical and Research Programs

Pediatric Psychopharmacology

Massachusetts General Hospital

Boston, Massachusetts

Learning Objectives

Module 1: Focus on Diagnosis

• You will be better able to recognize older adolescents and adults who should be screened for ADHD, and to diagnose ADHD in these age groups.

Module 2: Focus on Treatment in Adolescents and Adults

• You will be able to develop a multimodal treatment plan tailored to the individual patient, which may include medication, education, psychosocial treatment, organizational training, and accommodations in school and at work.
• You will be able to select and titrate pharmacologic treatments that affect symptomatic behavior and improve the functioning of your patients with ADHD, and to employ strategies for encouraging patient adherence to treatment.

Module 3: Applying Knowledge to Patient Care—Meet the Patient: “Grace”

• You will be able to develop an individualized, multimodal treatment plan with consideration for medical comorbidity for your patients with ADHD.
• You will be able to select and titrate pharmacologic treatments that affect symptomatic behavior and improve the functioning of your patients with ADHD, and to employ strategies for encouraging patient adherence to treatment.

Intended Audience
Psychiatrists, primary care physicians, and other clinicians who care for patients with ADHD

Accreditation/Designation of Credit Statements

Veritas Institute for Medical Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians
Module 1: Focus on Diagnosis
Veritas Institute for Medical Education, Inc. designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Module 2: Focus on Treatment in Adolescents and Adults
Veritas Institute for Medical Education, Inc. designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

To Receive CME/CE Credit

1. View/complete each module.
2. Complete and submit the CME Activity Evaluation and Request for Credit Form.
3. Print the CME/CE certificate or certificate of participation

This activity is provided free of charge to participants.

Disclaimer

The opinions expressed in this activity are those of the presenters and do not necessarily reflect those of Veritas Institute for Medical Education, Inc. or McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC. Please consult the appropriate package insert for full prescribing information on all drug therapies discussed.

Financial Disclosure Statements

In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME’s) Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Disclosures are as follows:

Birgit H. Amann, MD – Addrenex Pharmaceuticals, Inc (grant/research support); Bristol-Myers Squibb (speakers bureau); Forest Pharmaceuticals, Inc (consultant, speakers bureau); Eli Lilly and Company (consultant, speakers bureau, grant/research support); McNeil Pediatrics (consultant, speakers bureau, grant/research support); Novartis Pharmaceuticals (speakers bureau, grant/research support); Sepracor (speakers bureau); Shire (consultant, speakers bureau, grant/research support).

James J. McGough, MD, MS—Eli Lilly and Company (grant/research support), Shire (consultant).

Anthony L. Rostain, MD, MA – Eli Lilly and Company (speakers bureau); Ortho-McNeil-Janssen Pharmaceuticals, Inc (consultant, speakers bureau); Shire (consultant).

Timothy E. Wilens, MD―Abbott Laboratories (grant/research support, consultant); Eli Lilly and Company (grant/research support, speakers bureau, consultant); McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc (grant/research support, speakers bureau, consultant); Merck and Co, Inc (grant/research support, consultant); National Institutes of Health (National Institute on Drug Abuse) (grant/research support, consultant); Novartis Pharmaceuticals Corporation (speakers bureau, consultant); Shire (grant/research support, speakers bureau, consultant).

The staff of Veritas Institute for Medical Education, Inc. has nothing to disclose.

Unlabeled Use Disclosure Statement

Participants are advised that this CME activity may contain references to unlabeled/unapproved/investigational uses of drugs to treat ADHD.

Click on a module above to begin.

Copyright © 2009 Veritas Institute for Medical Education, Inc. All rights reserved.